Table 4. Comparison of NIHSS, SDS, mortality/morbidity ratio and RR-CVE between the two groups.
| AT (n = 160) | C (n = 160) | t/χ2 | p | |
| NIHSS on admission | 8.39 ± 3.21 | 8.16 ± 3.27 | 0.655 | 0.513 |
| D3-NIHSS | 8.44 ± 3.56 | 8.55 ± 3.47 | -0.286 | 0.775 |
| D7-NIHSS | 7.49 ± 4.23 | 6.76 ± 3.76 | 1.623 | 0.106 |
| D14-NIHSS | 6.12 ± 3.73 | 5.40 ± 3.49 | 1.746 | 0.082 |
| D14-SDS | 50.0% (78/156) | 49.0% (76/155) | 0.029 | 0.864 |
| M6-SDS | 23.4% (36/154) | 34.4% (53/154) | 4.567 | 0.033 |
| D14-mortality/morbidity ratio | 61.3% (98/160) | 66.3% (106/160) | 0.865 | 0.352 |
| M6-mortality/morbidity ratio | 32.1% (51/159) | 45.0% (72/160) | 5.623 | 0.018 |
| D14-RR-CVE | 4.4% (7/160) | 11.9% (19/160) | 6.028 | 0.014 |
| M6-RR-CVE | 10.7% (17/159) | 19.4% (31/160) | 4.704 | 0.030 |
AT, antihypertensive therapy; C, control; NIHSS, National Institutes of Health Stroke Scale; RR-CVE, recurrence rate of cardio-cerebral vascular events; SDS, significant dependent-survival status.